GenMark Diagnostics Company Profile (NASDAQ:GNMK)

About GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics logoGenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GNMK
  • CUSIP: N/A
  • Web: www.genmarkdx.com
Capitalization:
  • Market Cap: $656.04 million
  • Outstanding Shares: 47,087,000
Average Prices:
  • 50 Day Moving Avg: $12.07
  • 200 Day Moving Avg: $12.34
  • 52 Week Range: $8.03 - $13.67
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.75
  • P/E Growth: 9.99
Sales & Book Value:
  • Annual Revenue: $50.75 million
  • Price / Sales: 11.61
  • Book Value: $0.57 per share
  • Price / Book: 21.95
Profitability:
  • EBIDTA: ($45,600,000.00)
  • Net Margins: -101.61%
  • Return on Equity: -146.00%
  • Return on Assets: -70.45%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 2.00%
  • Quick Ratio: 1.57%
Misc:
  • Average Volume: 341,464 shs.
  • Beta: 1.04
  • Short Ratio: 12.42
 
Frequently Asked Questions for GenMark Diagnostics (NASDAQ:GNMK)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc. (NASDAQ:GNMK) posted its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $12.54 million during the quarter, compared to analyst estimates of $12.55 million. GenMark Diagnostics had a negative return on equity of 146.00% and a negative net margin of 101.61%. View GenMark Diagnostics' Earnings History.

Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?

5 brokerages have issued 1 year price objectives for GenMark Diagnostics' stock. Their forecasts range from $13.00 to $17.00. On average, they expect GenMark Diagnostics' stock price to reach $16.20 in the next year. View Analyst Ratings for GenMark Diagnostics.

What are analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:

  • 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (5/3/2017)
  • 2. Needham & Company LLC analysts commented, "GNMK's 4Q16 revenue was consistent with its 1/10/17 preannouncement while its EPS was in line with consensus. Management provided initial 2017 revenue guidance that bracketed consensus. As previously disclosed on 1/10/17, GNMK ended 2016 with more than 55 customer agreements for over 85 ePlex instruments which seems to bode well for ePlex demand. GNMK announced that it submitted its ePlex 510(k) to the FDA on 12/22/16 and noted that it expects to obtain CE Marks for its three blood culture panels in 2Q17. With the European ePlex launch underway and the U.S. ePlex launch set for mid-2017, we reiterate our Buy rating since we expect ePlex to drive a significant acceleration in revenue growth." (3/1/2017)

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:

  • James Charles Fox Ph.D., Independent Chairman of the Board
  • Hany Massarany, President, Chief Executive Officer, Director
  • Scott Mendel, Chief Financial Officer
  • Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
  • Eric Stier, Senior Vice President, General Counsel, Secretary
  • Jennifer Anne Williams, Senior Vice President - Human Resources
  • Michael W Gleeson, Senior Vice President, North American Commercial Operations
  • Michael S Kagnoff, Director
  • Daryl Jay Faulkner, Independent Director
  • Lisa M. Giles, Independent Director

Who owns GenMark Diagnostics stock?

GenMark Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Quantitative Systematic Strategies LLC (0.03%). Company insiders that own GenMark Diagnostics stock include Daryl Faulkner, Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

Who bought GenMark Diagnostics stock? Who is buying GenMark Diagnostics stock?

GenMark Diagnostics' stock was acquired by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Daryl Faulkner, Lisa M Giles, Michael Kagnoff and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

How do I buy GenMark Diagnostics stock?

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GenMark Diagnostics stock can currently be purchased for approximately $12.51.


MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.20 (29.50% upside)

Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/13/2017Needham & Company LLCBoost Price TargetBuy -> Buy$16.00 -> $17.00HighView Rating Details
6/12/2017Canaccord GenuityReiterated RatingBuy$17.00MediumView Rating Details
5/17/2017BTIG ResearchReiterated RatingBuy$17.00MediumView Rating Details
9/16/2016Cowen and CompanyUpgradeMarket Perform -> Outperform$17.00N/AView Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetOverweight$10.00 -> $13.00N/AView Rating Details
2/26/2016Raymond James Financial, Inc.Lower Price TargetOutperform$9.00 -> $7.25N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for GenMark Diagnostics (NASDAQ:GNMK)
Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Earnings History by Quarter for GenMark Diagnostics (NASDAQ GNMK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.28)($0.30)$12.55 million$12.54 millionViewListenView Earnings Details
2/28/2017Q416($0.27)($0.27)$15.03 million$14.90 millionViewListenView Earnings Details
11/3/2016Q316($0.31)($0.27)$10.36 million$10.80 millionViewN/AView Earnings Details
7/28/2016Q216($0.33)($0.30)$9.62 million$12.50 millionViewListenView Earnings Details
5/3/2016Q116($0.29)($0.30)$10.67 million$11.06 millionViewN/AView Earnings Details
2/23/2016Q415($0.27)($0.21)$12.34 million$13.20 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.27)$8.24 million$8.80 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.29)$7.59 million$7.65 millionViewN/AView Earnings Details
5/5/2015Q115($0.24)($0.24)$10.10 million$10.10 millionViewN/AView Earnings Details
2/24/2015Q414($0.28)($0.21)$9.83 million$9.83 millionViewN/AView Earnings Details
10/30/2014Q314($0.32)($0.23)$5.80 million$6.30 millionViewN/AView Earnings Details
8/11/2014Q214($0.29)($0.27)$4.79 million$6.55 millionViewN/AView Earnings Details
5/6/2014Q114($0.25)($0.21)$6.40 million$7.91 millionViewN/AView Earnings Details
3/11/2014Q413($0.22)($0.21)$6.06 million$6.45 millionViewN/AView Earnings Details
11/12/2013Q313($0.27)($0.24)$4.60 million$4.64 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.26)($0.25)$5.05 million$5.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$9.53 million$11.10 millionViewN/AView Earnings Details
11/10/2011($0.32)($0.31)ViewN/AView Earnings Details
8/5/2011($0.45)($0.39)ViewN/AView Earnings Details
5/9/2011($0.49)($0.56)ViewN/AView Earnings Details
3/3/2011($0.52)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GenMark Diagnostics (NASDAQ:GNMK)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.55 EPS

Dividends

Dividend History for GenMark Diagnostics (NASDAQ:GNMK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GenMark Diagnostics (NASDAQ:GNMK)
Insider Ownership Percentage: 7.50%
Institutional Ownership Percentage: 92.58%
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2017Michael GleesonSVPSell357$12.89$4,601.73View SEC Filing  
5/19/2017Hany MassaranyInsiderSell8,239$12.89$106,200.71View SEC Filing  
5/19/2017Michael GleesonSVPSell1,916$12.89$24,697.24View SEC Filing  
5/19/2017Scott MendelCFOSell2,135$12.89$27,520.15View SEC Filing  
5/16/2017Scott MendelCFOSell1,268$13.43$17,029.24View SEC Filing  
5/2/2017Eric StierSVPSell362$13.34$4,829.08View SEC Filing  
5/2/2017Hany MassaranyInsiderSell1,571$13.34$20,957.14View SEC Filing  
5/2/2017Scott MendelCFOSell232$13.34$3,094.88View SEC Filing  
3/3/2017Michael GleesonSVPSell353$12.29$4,338.37View SEC Filing  
2/21/2017Hany MassaranyInsiderSell33,537$10.08$338,052.96View SEC Filing  
2/21/2017Jon Faiz KayyemSVPSell5,250$10.08$52,920.00View SEC Filing  
2/21/2017Scott MendelCFOSell8,595$10.08$86,637.60View SEC Filing  
2/2/2017Hany MassaranyInsiderSell1,142$11.58$13,224.36View SEC Filing  
2/2/2017Jennifer Anne WilliamsSVPSell332$11.58$3,844.56View SEC Filing  
2/2/2017Scott MendelCFOSell235$11.58$2,721.30View SEC Filing  
1/19/2017Hany MassaranyInsiderSell27,124$12.47$338,236.28View SEC Filing  
1/19/2017Michael GleesonSVPSell9,569$12.47$119,325.43View SEC Filing  
1/19/2017Scott MendelCFOSell9,098$12.47$113,452.06View SEC Filing  
12/5/2016Jennifer Anne WilliamsSVPSell336$11.31$3,800.16View SEC Filing  
12/2/2016Michael GleesonSVPSell357$11.30$4,034.10View SEC Filing  
11/22/2016Michael KagnoffDirectorBuy2,000$11.80$23,600.00View SEC Filing  
11/14/2016Michael KagnoffDirectorBuy2,000$12.50$25,000.00View SEC Filing  
11/2/2016Hany MassaranyInsiderSell1,148$10.30$11,824.40View SEC Filing  
11/2/2016Michael GleesonSVPSell400$10.30$4,120.00View SEC Filing  
9/7/2016Hany MassaranyInsiderSell1,186$8.69$10,306.34View SEC Filing  
9/7/2016Jennifer Anne WilliamsSVPSell523$8.69$4,544.87View SEC Filing  
9/2/2016Jon Faiz KayyemSVPSell133$8.62$1,146.46View SEC Filing  
8/29/2016Jennifer Anne WilliamsSVPSell24,172$8.63$208,604.36View SEC Filing  
8/22/2016Michael GleesonSVPSell7,500$9.00$67,500.00View SEC Filing  
8/12/2016Lisa M GilesDirectorBuy823$9.40$7,736.20View SEC Filing  
8/2/2016Eric StierSVPSell367$9.88$3,625.96View SEC Filing  
8/2/2016Hany MassaranyInsiderSell1,147$9.88$11,332.36View SEC Filing  
6/7/2016Hany MassaranyCEOSell1,188$8.98$10,668.24View SEC Filing  
6/7/2016Michael GleesonSVPSell868$8.80$7,638.40View SEC Filing  
6/3/2016Ingo ChakravartySVPSell184$8.53$1,569.52View SEC Filing  
5/9/2016Ingo ChakravartySVPSell582$5.42$3,154.44View SEC Filing  
5/2/2016Eric StierSVPSell363$5.79$2,101.77View SEC Filing  
5/2/2016Hany MassaranyCEOSell1,160$5.79$6,716.40View SEC Filing  
3/10/2016Michael KagnoffDirectorBuy2,500$4.90$12,250.00View SEC Filing  
3/7/2016Hany MassaranyCEOSell1,193$5.76$6,871.68View SEC Filing  
3/7/2016Michael GleesonSVPSell559$5.76$3,219.84View SEC Filing  
3/2/2016Eric StierSVPSell365$4.87$1,777.55View SEC Filing  
2/9/2016Ingo ChakravartySVPSell697$5.04$3,512.88View SEC Filing  
2/3/2016Hany MassaranyCEOSell9,173$4.99$45,773.27View SEC Filing  
2/3/2016Michael GleesonSVPSell3,083$4.99$15,384.17View SEC Filing  
1/21/2016Hany MassaranyCEOSell648$6.80$4,406.40View SEC Filing  
1/21/2016Michael GleesonSVPSell227$6.80$1,543.60View SEC Filing  
12/8/2015Eric StierSVPSell240$7.26$1,742.40View SEC Filing  
12/8/2015Hany MassaranyCEOSell1,735$7.26$12,596.10View SEC Filing  
12/3/2015Hany MassaranyCEOSell3,571$7.71$27,532.41View SEC Filing  
12/3/2015Michael GleesonSVPSell1,664$7.62$12,679.68View SEC Filing  
11/3/2015Lisa M GilesDirectorBuy4,000$6.60$26,400.00View SEC Filing  
10/30/2015Michael KagnoffDirectorBuy5,000$6.70$33,500.00View SEC Filing  
10/30/2015Scott MendelCFOBuy10,000$6.47$64,700.00View SEC Filing  
10/29/2015Daryl FaulknerDirectorBuy4,000$7.33$29,320.00View SEC Filing  
9/15/2015Jennifer Anne WilliamsSVPSell14,245$9.98$142,165.10View SEC Filing  
9/14/2015Jennifer Anne WilliamsSVPSell9,245$10.00$92,450.00View SEC Filing  
9/11/2015Hany MassaranyCEOSell1,683$9.64$16,224.12View SEC Filing  
9/11/2015Jennifer Anne WilliamsSVPSell18,280$9.99$182,617.20View SEC Filing  
9/4/2015Jennifer Anne WilliamsSVPSell1,867$9.59$17,904.53View SEC Filing  
9/2/2015Hany MassaranyCEOSell3,865$9.62$37,181.30View SEC Filing  
8/24/2015Scott MendelCFOBuy10,000$9.10$91,000.00View SEC Filing  
6/16/2015Hany MassaranyCEOSell1,698$9.12$15,485.76View SEC Filing  
6/4/2015Michael GleesonSVPSell1,595$9.55$15,232.25View SEC Filing  
6/3/2015Hany MassaranyCEOSell3,486$9.47$33,012.42View SEC Filing  
4/9/2015Hany MassaranyCEOSell5,942$11.52$68,451.84View SEC Filing  
3/13/2015Jennifer Anne WilliamsSVPSell30,000$12.56$376,800.00View SEC Filing  
3/11/2015Hany MassaranyCEOSell28,110$11.88$333,946.80View SEC Filing  
3/11/2015Jeffrey Alan HawkinsSVPSell6,832$12.01$82,052.32View SEC Filing  
3/10/2015Jennifer Anne WilliamsSVPSell722$11.83$8,541.26View SEC Filing  
3/10/2015Michael KagnoffDirectorBuy5,000$11.84$59,200.00View SEC Filing  
3/9/2015Ingo ChakravartySVPSell3,310$12.06$39,918.60View SEC Filing  
1/22/2015Hany MassaranyCEOSell5,982$12.88$77,048.16View SEC Filing  
1/7/2015Hany MassaranyCEOSell4,858$13.00$63,154.00View SEC Filing  
12/16/2014Kevin C OboyleDirectorSell291$12.40$3,608.40View SEC Filing  
12/15/2014Eric StierSVPSell235$12.51$2,939.85View SEC Filing  
12/15/2014Hany MassaranyCEOSell1,700$12.51$21,267.00View SEC Filing  
12/4/2014Hany MassaranyCEOSell3,300$12.06$39,798.00View SEC Filing  
12/4/2014Jeffrey Alan HawkinsSVPSell1,350$12.06$16,281.00View SEC Filing  
10/31/2014Jon Faiz KayyemSVPSell6,000$11.01$66,060.00View SEC Filing  
10/8/2014Hany MassaranyCEOSell5,804$9.00$52,236.00View SEC Filing  
10/7/2014Michael GleesonSVPSell55$9.10$500.50View SEC Filing  
9/12/2014Hany MassaranyCEOSell1,678$9.86$16,545.08View SEC Filing  
9/5/2014Hany MassaranyCEOSell3,795$10.04$38,101.80View SEC Filing  
9/5/2014Michael GleesonSVPSell1,833$10.04$18,403.32View SEC Filing  
8/7/2014Michael GleesonSVPSell52$11.15$579.80View SEC Filing  
7/1/2014Jon Faiz KayyemSVPSell6,000$13.60$81,600.00View SEC Filing  
6/11/2014Hany MassaranyCEOSell1,115$11.64$12,978.60View SEC Filing  
6/5/2014Jon Faiz KayyemSVPSell1,483$10.69$15,853.27View SEC Filing  
6/3/2014Hany MassaranyCEOSell2,700$10.67$28,809.00View SEC Filing  
5/29/2014Kevin C OboyleDirectorSell1,603$10.98$17,600.94View SEC Filing  
5/28/2014Jon Faiz KayyemSVPSell6,000$11.06$66,360.00View SEC Filing  
5/8/2014Richard SlanskyCFOSell2,302$9.26$21,316.52View SEC Filing  
4/9/2014Hany MassaranyCEOSell3,985$9.87$39,331.95View SEC Filing  
3/26/2014Jennifer Anne WilliamsSVPSell30,195$9.97$301,044.15View SEC Filing  
3/5/2014Jon Faiz KayyemSVPSell7,355$12.46$91,643.30View SEC Filing  
1/16/2014Jon Faiz KayyemSVPSell50,000$14.05$702,500.00View SEC Filing  
1/7/2014Hany MassaranyCEOSell4,698$13.31$62,530.38View SEC Filing  
12/6/2013Michael GleesonSVPSell2,211$11.14$24,630.54View SEC Filing  
12/4/2013Hany MassaranyCEOSell3,968$11.14$44,203.52View SEC Filing  
10/9/2013Hany MassaranyCEOSell3,925$12.05$47,296.25View SEC Filing  
10/1/2013Jon Faiz KayyemSVPSell6,000$12.14$72,840.00View SEC Filing  
9/4/2013Jeffrey Alan HawkinsSVPSell1,890$11.60$21,924.00View SEC Filing  
9/3/2013Hany MassaranyCEOSell2,354$11.60$27,306.40View SEC Filing  
9/3/2013Jon Faiz KayyemSVPSell1,545$11.60$17,922.00View SEC Filing  
8/20/2013Jon Faiz KayyemSVPSell1,310$10.15$13,296.50View SEC Filing  
7/1/2013Jon Faiz KayyemSVPSell6,000$10.40$62,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for GenMark Diagnostics (NASDAQ:GNMK)
Latest Headlines for GenMark Diagnostics (NASDAQ:GNMK)
Source:
DateHeadline
americanbankingnews.com logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Expected to Announce Quarterly Sales of $12.61 Million
www.americanbankingnews.com - July 16 at 8:58 AM
americanbankingnews.com logo Brokerages Expect GenMark Diagnostics, Inc. (GNMK) to Announce -$0.31 EPS
www.americanbankingnews.com - July 14 at 1:24 PM
americanbankingnews.com logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 8:55 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for GenMark Diagnostics, Inc.'s FY2018 Earnings (GNMK)
www.americanbankingnews.com - July 3 at 9:41 AM
streetinsider.com logoGenMark Diagnostics (GNMK) Announces CE Mark for ePlex Blood Culture Identification Gram-Positive and Gram-Negative Panels
www.streetinsider.com - June 29 at 11:08 PM
finance.yahoo.com logoGenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels
finance.yahoo.com - June 29 at 11:08 PM
streetinsider.com logoGenMark Diagnostics (GNMK) Commences $65M Common Stock Offering
www.streetinsider.com - June 14 at 11:56 AM
finance.yahoo.com logoGenMark Diagnostics Prices Upsized Public Offering of Common Stock
finance.yahoo.com - June 13 at 10:21 PM
americanbankingnews.com logoNeedham & Company LLC Raises GenMark Diagnostics, Inc. (GNMK) Price Target to $17.00
www.americanbankingnews.com - June 13 at 8:14 AM
finance.yahoo.com logoGenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen Panel
finance.yahoo.com - June 12 at 6:17 PM
finance.yahoo.com logoGenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : June 12, 2017
finance.yahoo.com - June 12 at 6:17 PM
finance.yahoo.com logoGenMark Diagnostics Commences Public Offering of Common Stock
finance.yahoo.com - June 12 at 6:17 PM
americanbankingnews.com logoGenMark Diagnostics, Inc. (GNMK) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - June 12 at 1:48 PM
americanbankingnews.com logoGenMark Diagnostics, Inc. (GNMK) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 12 at 10:58 AM
finance.yahoo.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : June 9, 2017
finance.yahoo.com - June 9 at 10:10 AM
americanbankingnews.com logoValuEngine Upgrades GenMark Diagnostics, Inc (GNMK) to "Hold"
www.americanbankingnews.com - June 4 at 2:32 PM
finance.yahoo.com logoGenMark Diagnostics to Present at the 2017 William Blair Growth Stock Conference
finance.yahoo.com - May 31 at 10:26 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $13.98 Million
www.americanbankingnews.com - May 27 at 9:48 AM
finance.yahoo.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 26, 2017
finance.yahoo.com - May 26 at 6:08 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) CFO Scott Mendel Sells 2,135 Shares
www.americanbankingnews.com - May 23 at 8:35 PM
americanbankingnews.com logoMichael Gleeson Sells 1,916 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - May 23 at 8:34 PM
americanbankingnews.com logoInsider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 8,239 Shares of Stock
www.americanbankingnews.com - May 23 at 8:18 PM
americanbankingnews.com logoScott Mendel Sells 1,268 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - May 17 at 11:32 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Receives Buy Rating from BTIG Research
www.americanbankingnews.com - May 17 at 1:32 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 16 at 8:42 AM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Short Interest Update
www.americanbankingnews.com - May 11 at 9:06 AM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Insider Hany Massarany Sells 1,571 Shares
www.americanbankingnews.com - May 6 at 12:58 AM
finance.yahoo.com logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 5, 2017
finance.yahoo.com - May 5 at 10:41 PM
finance.yahoo.com logoETFs with exposure to GenMark Diagnostics, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 5:39 PM
americanbankingnews.com logoInsider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 1,571 Shares of Stock
www.americanbankingnews.com - May 4 at 10:42 PM
finance.yahoo.com logoGenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 12:07 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 4 at 12:22 AM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Issues Earnings Results
www.americanbankingnews.com - May 3 at 10:28 PM
finance.yahoo.com logoGenMark Diagnostics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 3 at 10:16 PM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 9:34 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - May 3 at 3:17 PM
finance.yahoo.com logoEdited Transcript of GNMK earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 8:47 AM
finance.yahoo.com logoInvestor Network: GenMark Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 7:31 PM
finance.yahoo.com logoGenMark Diagnostics reports 1Q loss
finance.yahoo.com - May 2 at 7:31 PM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Earns Daily Media Sentiment Rating of 0.26
www.americanbankingnews.com - April 30 at 1:53 PM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Earns Media Sentiment Score of 0.12
www.americanbankingnews.com - April 27 at 11:50 PM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Getting Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 24 at 4:52 PM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Given Media Impact Score of 0.39
www.americanbankingnews.com - April 21 at 8:46 PM
businesswire.com logoGenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel
www.businesswire.com - April 21 at 5:27 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 21 at 9:23 AM
finance.yahoo.com logoCORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel
finance.yahoo.com - April 20 at 5:35 PM
finance.yahoo.com logoGenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017
finance.yahoo.com - April 19 at 11:50 AM
americanbankingnews.com logoGenMark Diagnostics (GNMK) Earns Daily News Impact Rating of -0.12
www.americanbankingnews.com - April 18 at 1:56 PM
finance.yahoo.com logoETFs with exposure to GenMark Diagnostics, Inc. : April 13, 2017
finance.yahoo.com - April 13 at 5:18 PM
americanbankingnews.com logoGenMark Diagnostics, Inc (GNMK) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 11 at 11:33 PM

Social

Chart

GenMark Diagnostics (GNMK) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff